Based on the key indicators related to Tscan Therapeutics' liquidity, profitability, solvency, and operating efficiency, Tscan Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Tscan Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 120.1 M in 2024, whereas Total Assets are likely to drop slightly above 166.9 M in 2024. Key indicators impacting Tscan Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Tscan Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Tscan Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tscan Therapeutics.
Net Income
(84.76 Million)
Tscan
Select Account or Indicator
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Capital Stock
Net Working Capital
Short Term Debt
Property Plant Equipment
Other Liab
Non Current Liabilities Other
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Tscan Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tscan Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Tscan Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Tscan Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tscan Therapeutics. Check Tscan Therapeutics' Beneish M Score to see the likelihood of Tscan Therapeutics' management manipulating its earnings.
Tscan Therapeutics Stock Summary
Tscan Therapeutics competes with Apellis Pharmaceuticals, Iteos Therapeutics, Day One, Acumen Pharmaceuticals, and X4 Pharmaceuticals. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Tscan Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 115 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Tscan Therapeutics's current stock value. Our valuation model uses many indicators to compare Tscan Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tscan Therapeutics competition to find correlations between indicators driving Tscan Therapeutics's intrinsic value. More Info.
Tscan Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Tscan Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tscan Therapeutics' earnings, one of the primary drivers of an investment's value.
Tscan Therapeutics Systematic Risk
Tscan Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tscan Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Tscan Therapeutics correlated with the market. If Beta is less than 0 Tscan Therapeutics generally moves in the opposite direction as compared to the market. If Tscan Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tscan Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tscan Therapeutics is generally in the same direction as the market. If Beta > 1 Tscan Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Tscan Therapeutics Thematic Clasifications
Tscan Therapeutics is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
Today, most investors in Tscan Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tscan Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tscan Therapeutics growth as a starting point in their analysis.
Tscan Therapeutics November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tscan Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tscan Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tscan Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Tscan Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tscan Therapeutics's daily price indicators and compare them against related drivers.
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.